Trials / Unknown
UnknownNCT02717091
Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer
Phase II Study of Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Nagoya University · Academic / Other
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to clarify the efficacy and safety of neoadjuvant FOLFIRINOX and nab-paclitaxel + gemcitabine for borderline resectable pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FOLFIRINOX | |
| DRUG | gemcitabine + nab-paclitaxel |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2020-06-01
- Completion
- 2023-06-01
- First posted
- 2016-03-23
- Last updated
- 2020-09-10
Source: ClinicalTrials.gov record NCT02717091. Inclusion in this directory is not an endorsement.